Results for study population translation from English to Slovenian

study population
klinična raziskava

itp study population
itp študijska populacija

total study population
skupna populacija študije

endpoint / study population
opazovani dogodek / v študiji sodelujoča populacija

overall study population; n=454
celotna študijska populacija; n=454

40% of the tropos study population)].
analizo a posteriori so izvedli tudi pri podskupini bolnic iz študije tropos, ki so bile zlasti medicinsko zanimive in imele veliko tveganje za zlome [opredeljeno kot mkg vratu stegnenice vrednost t ≤ - 3 sd (izdelovalčev razpon je ustrezal - 2, 4 sd po merilih nhanes iii – national health and nutrition examination survey iii) in starost ≥ 74 let (n = 1977, se pravi 40% populacije v študiji tropos)].

the mean age of the study population was 37.9 years.
povprečna starost populacije študije je bila 37,9 let.

braf mutations were reported in 13% of the study population.
mutacije braf so bile ugotovljene pri 13 % študijske populacije.

safety and tolerability was evaluated in the entire study population.
varnost in prenašanje so ocenili v celotni študijski populaciji.

description of any difference between the reference and the study population,
opis vsake razlike med referenčno in raziskovano populacijo,

prevention of hz cases with severe pain in the entire sps study population
preprečevanje primerov herpesa zostra s hudo bolečino v celotni populaciji študije sps

description of any difference between the reference population and the study population,
opis vseh razlik med referenčno populacijo in raziskovano populacijo,

immunogenicity was assessed in a subset (n=197) of study population.
imunogenita bola hodnotená v podskupine (n=197) štúdie populácie.

additionally, 45% of the study population also received long-acting nitrates.
poleg tega je 45 % populacije, ki je sodelovala v študiji, prejemalo tudi dolgo delujoče nitrate.

immunogenicity was assessed in a subset (n=182) of the study population.
imunogenita bola hodnotená v podskupine (n=182) štúdie populácie.

hcv study population (in combination with anti-viral interferon and ribavirin therapy)
hcv študijska populacija (v kombinaciji s protivirusnim interferonskim zdravljenjem in zdravljenjem z ribavirinom)

approximately half of the study population had at least two of the cardiovascular history entry criteria.
približno polovica populacije, vključene v študijo, je ustrezala vsaj dvema vstopnima kriterijema kardiovaskularne anamneze.

the estimated glomerular filtration rate (egfr) did not change for the study population over time.
ocenjena hitrost glomerulne filtracije (egfr) je pri proučevani populaciji ves čas ostala enaka.

overall 12% of the combined study population had an abnormal pap test suggestive of cin at day 1.
v celoti je 12 % vseh v študijo vključenih oseb imelo 1. dan nenormalni pap test, ki je kazal na cin.

1 represents the highest frequency observed either in the healthy adult or healthy older study population.
1 predstavlja največjo pogostnost, ugotovljeno bodisi v populaciji zdravih odraslih oseb bodisi populaciji zdravih starostnikov.